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  NOT PRECEDENTIAL
UNITED STATES COURT OF APPEALS
FOR THE THIRD CIRCUIT
                
No. 06-3123
                 
UNITED STATES OF AMERICA
      v.
MAHMOUD ABUARQUOB,
also known as MAHAMOUD ABUARQOUB,
also known as MAHMOUD ARQOUB,
also known as MAHAMOUD A. ABU-ARQOUB,
also known as MAHAMOUD A. ARGOUB
Mahmoud Abuarquob,
                                                   Appellant
                                           
On Appeal from the United States District Court
for the District of New Jersey
(D. C. No. 05-cr-00573)
District Judge:  Hon. Freda Wolfson
                                            
Submitted under Third Circuit LAR 34.1(a)
on June 26, 2008
Before:  SLOVITER, BARRY and ROTH, Circuit Judges
(Opinion filed: October 3, 2008)
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O P I N I O N
                    
ROTH, Circuit Judge:
Mahmoud Abuarquob appeals the judgment of conviction and sentence entered by the
District Court for the District of New Jersey relating to one count of mail fraud, in violation
of 18 U.S.C. § 1341 (Count One), one count of introducing an unapproved new drug into
interstate commerce while acting with intent to defraud, in violation of 21 U.S.C. §§ 331(d),
333(a)(2), and 355(a) (Count Two), one count of introducing a misbranded drug into
interstate commerce while acting with intend to defraud, in violation of 21 U.S.C. §§ 331(a),
333(a)(2) (Count Three), one count of wholesale distribution of drugs without a license, in
violation of 21 U.S.C. §§ 331(t), 333(b)(1)(D), and 353(e)(2)(A) (Count Four), and one count
of knowing or fraudulent importation, in violation of 18 U.S.C. § 545 (Count Five).  For the
reasons stated below, we will affirm the judgment of the District Court. 
I.  Background
On October 27, 2004, Abuarquob, representing himself as an agent of Safad
Corporation, approached Shore Memorial Hospital and offered to sell it Aventis Vaxigrip flu
vaccine.  This flu vaccine was not approved for use in the United States by the Food and
Drug Administration (FDA).  Abuarquob told Barbara Giocomelli, the Pharmacy Director
3at Shore Memorial, that given the current nationwide flu vaccine shortage, there was a lot of
money to be made with these Vaxigrip flu vaccines.  After Giocomelli informed Abuarquob
that she did not believe Vaxigrip was approved for sale in the U. S., Abuarquob responded
that the flu vaccine was in fact FDA-approved and was sold throughout New York.
Abuarquob made similar assurances to others in his attempts to sell Vaxigrip. 
Abuarquob was reported to the FDA by Giocomelli, who agreed to cooperate with the
FDA in procuring evidence against Abuarquob.  In a monitored telephone call, Giocomelli
agreed to purchase 5,000 Vaxigrip flu vaccines for $55 per unit.  Abuarquob then sent a fax,
which represented that Vaxigrip was FDA-approved, to Giocomelli, confirming the
transaction.  In addition, Abuarquob requested that a “letter of commitment/purchase order”
be addressed to Safad at an address which turned out to be Abuarquob’s home.  Abuarquob
picked up the letter and told Giocomelli that the Vaxigrip vaccines would be delivered on
November 8, 2004.  On that date, Abuarquob called Giocomelli and told her that DHL, the
carrier chosen by Abuarquob, had shipped the vaccines to the wrong location and that he was
going to leave the country to get the vaccines himself. 
On November 17, 2004, Customs and Border protection officers seized the DHL
shipment of Vaxigrip, which had originated in Saudi Arabia.  The officers disguised
themselves as DHL employees and attempted a controlled delivery to Abuarquob’s home,
but no one was there.  The officers left instructions on how to retrieve the package.  They
were called later that day by a woman, claiming to represent Safad.  She scheduled a delivery
4time.  The officers made the delivery to this woman – who turned out to be Abuarquob’s wife
– and then executed a search warrant.  Abuarquob’s wife put the officers in contact with
Abuarquob, who once again insisted that Vaxigrip was FDA-approved.  Abuarquob was
arrested on reentering the country at Philadelphia International Airport on December 4 .th
A Grand Jury indicted Abuarquob on the five counts listed above, and his trial
commenced on January 9, 2006.  At the close of the government’s case, Abuarquob filed two
motions for acquittal pursuant to Federal Rule of Criminal Procedure 29.  The first motion
asserted that there was insufficient evidence to convict him on Count One because the
government had proven that the vaccines were delivered by DHL rather then by “mail” as
the indictment charged.  Abuarquob argued that the word “mail” as found in 18 U.S.C. §
1341 refers exclusively to the province of the United States Postal Service, as opposed to a
private commercial carrier like DHL.  Thus, Abuarquob asserted that to convict him would
represent  an unconstitutional constructive amendment of his indictment.  The District Judge
reserved decision on the motion until after the jury’s verdict, at which time she denied the
motion in a written opinion.
The second motion asserted that there was insufficient evidence of fraudulent intent
– a necessary element of Counts One, Two, Three, and Five – on the part of Abuarquob.  The
District Court denied this motion after argument. 
The District Court had subject matter jurisdiction under 18 U.S.C. § 3231.  We have
appellate jurisdiction under 28 U.S.C. § 1291.  
      Section 1341was expanded in 1994 when Congress amended it to broaden its language1
to include private or commercial carriers.  As a result of that amendment, the plain text of
§ 1341 refers to the use of transmission facilities both in the context of the Postal Service and
of private or commercial carriers.  See 18 U.S.C. § 1341.  In addition, this Court has
previously stated that “[t]he substantive elements of mail fraud under § 1341 are . . . the use
of the mails–whether the United States Postal Service or a private carrier–in furtherance of
the fraudulent scheme,” Dobson, 419 F.3d at 236-37, and that “[w]e use the term ‘mail’ and
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II.  Discussion
On appeal, Abuarquob repeats his arguments detailed above. 
In regard to Abuarquob’s first claim, we exercise plenary review over issues of
statutory interpretation.  Gibbs v. Cross, 160 F.3d 962, 964 (3d Cir. 1998).  Similarly, “[w]e
exercise plenary review in determining whether there was a constructive amendment of the
indictment and whether there was a variance between the indictment and the proofs at trial.”
United States v. Dario, 445 F.3d 253, 259 (3d Cir. 2006).
A constructive amendment occurs “where a defendant is deprived of his ‘substantial
right to be tried only on charges presented in an indictment returned by a grand jury.’”
United States v. Syme, 276 F.3d 131, 148 (3d Cir. 2002) (quoting United States v. Miller, 471
U.S. 130, 140 (1985).  “In order to rise to the level of an impermissible amendment, a
variance must act to modify the indictment so that the defendant is convicted of a crime that
involves elements distinct from those of the crimes with which he was originally charged.”
United States v. Asher, 854 F.2d 1483, 1497 (3d Cir. 1988).  Here, however, even assuming
that delivery by “mail” or “private carrier” were two distinct crimes as Abuarquob asserts,1
‘mailing’ to include any mode of delivery covered by the mail fraud statute.”  United States
v. Tiller, 302 F.3d 98, 101 n.2 (3d Cir. 2002). 
     There has also been no prejudicial variance because “the indictment sufficiently2
inform[ed] [Abuarquob] of the charges against him so that he [could] prepare his defense and
not be misled or surprised at trial.”  Dario, 445 F.3d at 262.  Indeed, while the indictment
charged Abuarquob with delivery by mail, it also detailed the DHL shipment that was at the
center of the government’s case.
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they still share the same elements.  See United States v. Dobson, 419 F.3d 231, 236-37 (3d
Cir. 2005).  Therefore, there has been no unconstitutional constructive amendment of
Abuarquob’s indictment.2
In regard to Abuarquob’s second claim, our review of a challenge to the sufficiency
of evidence is plenary, United States v. Taftsiou, 144 F.3d 287, 290 (3d Cir. 1998).  “We
must determine whether the evidence submitted at trial, when viewed in the light most
favorable to the government, would allow a rational trier of fact to convict.”  United States
v. Hart, 273 F.3d 363, 371 (3d Cir. 2001) (internal quotations omitted).  
The facts contained in the record, viewed in the light most favorable to the
government, lead us to the conclusion that there was more than sufficient evidence for a jury
to find beyond a reasonable doubt that Abuarquob knew or was willfully blind to the fact that
Vaxigrip was not FDA-approved.  Abuarquob attained a printout from the FDA’s website
showing that another flu vaccine, Fluzone, was FDA-approved, evincing his awareness of
the simple process of verifying a drug’s status online.  Still, Abuarquob repeatedly asserted
– orally and in writing – that Vaxigrip was FDA-approved.  He also acknowledged the
nationwide flu vaccine shortage and potential profits to be reaped by sales of Vaxigrip.  We
     Abuarquob argues that he relied on his supplier’s assurance that Vaxigrip was FDA-3
approved, and that his transparent conduct–he openly gave out his name, address, and
telephone number in his attempts to sell Vaxigrip–show that he did not have the requisite
intent.  However, these facts are insufficient to overturn a well-reasoned jury verdict.
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find that these facts could lead a reasonable jury to believe that Abuarquob knew or was
willfully blind to the fact that Vaxigrip was not FDA-approved.  3
III.  Conclusion
For the foregoing reasons, we will affirm the judgment of the District Court.
